Read by QxMD icon Read

Therapeutic Delivery

Didem Şen Karaman, Suvi Manner, Jessica M Rosenholm
No abstract text is available yet for this article.
March 2, 2018: Therapeutic Delivery
Giuseppe Cavallaro, Giuseppe Lazzara, Rawil Fakhrullin
The review provides an overview of the mesoporous inorganic particles employed as drug delivery systems for controlled and sustained release of drugs. We have classified promising nanomaterials for drug delivery on the basis of their natural or synthetic origin. Nanoclays are available in different morphologies (nanotubes, nanoplates and nanofibers) and they are typically available at low cost from natural resources. The surface chemistry of nanoclays is versatile for targeted modifications to control loading and release properties...
March 2, 2018: Therapeutic Delivery
Sangram Raut, Jean-Louis Dasseux, Nirupama A Sabnis, Linda Mooberry, Andras Lacko
The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time in the circulation and biocompatibility. The purpose of this review is to briefly discuss current findings with the focus on each type of formulation's potential for clinical applications. Regarding utilizing lipoprotein type formulation for cancer therapeutics, their potential for tumor-selective delivery is also discussed...
March 2, 2018: Therapeutic Delivery
Khaled Greish, Aanchal Mathur, Moiz Bakhiet, Sebastien Taurin
By the end of 2017 more than 200,000 scientific research articles had been published about nanomedicine. Out of this vast number only a few of the reported nanoconstructs reached clinical trials for various applications, including the diagnosis and treatment of several cancers, and the treatment of infections and other non-cancerous diseases. 30 years after the pioneering work in this field of research, the low product yield at the end of research pipeline leads to a question that is asked by many: 'had nanomedicine been lost in translation?' In this review, we will discuss the landscape of nanomedicine regarding cancer treatment and miscellaneous applications as well as some obstacles toward full utilization of this powerful therapeutic tool and suggest a few solutions to improve the current translational value of nanomedicine research...
March 2, 2018: Therapeutic Delivery
Sourav Bhattacharjee
No abstract text is available yet for this article.
March 2, 2018: Therapeutic Delivery
Nitin Joshi
No abstract text is available yet for this article.
March 2, 2018: Therapeutic Delivery
Per G Djupesland
Per G Djupesland, MD, PhD speaks to Hannah Makin, Commissioning Editor: Dr Djupesland is the inventor of OptiNose®'s patented, bi-directional nasal drug-delivery technology and is a Co-Founder of OptiNose AS. Dr. Djupesland is a lead inventor on all 38 OptiNose patent families/patent applications, and serves as Chief Scientific Officer of OptiNose AS, with primary responsibility for device discovery and early development efforts. These early development efforts include identifying new product opportunities that use bi-directional technology, advancing the design of devices using the bi-directional technology to treat a variety of medical conditions and conducting Phase I and IIa trials with new 'nose-to-brain' applications for the technology...
February 1, 2018: Therapeutic Delivery
Rinti Banerjee
No abstract text is available yet for this article.
March 2018: Therapeutic Delivery
Ya Xiao, Jiajia Huang, Jiajia Xu, Liuwei Zeng, Jiaran Tian, Yunru Lou, Yuxue Liu, Bo Hu, Fei Tong, Ruilin Shen
AIM: To synthesize a puerarin nanoparticle based on glycyrrhetinic acid (GA)-PEG-PBLA and evaluate it in vivo. MATERIALS & METHODS: In this study, drug nanoparticle was synthesized, characterized and assessed as puerarin delivery system. Nanoparticle GA-PEG-PBLA could combine with puerarin via hydrophobic interaction to form the compound. Puerarin could be quickly and efficiently loaded via the nanoparticle GA-PEG-PBLA at pH 7.4. Further, GA-PEG-PBLA-mediated puerarin delivery system could target for the liver that had GA receptor binding...
March 1, 2018: Therapeutic Delivery
Mariana Medina-Sánchez, Haifeng Xu, Oliver G Schmidt
Micro- and nano-motors are emerging as novel drug delivery platforms, offering advantages such as rapid drug transport, high tissue penetration and motion controllability. They can be propelled and/or guided by endogenous (i.e., chemotaxis) or exogenous stimuli (e.g., ultrasound, magnetic fields, light) toward the area of interest. Moreover, such stimuli can be used to trigger the release of a therapeutic payload when the motor reaches certain location in order to improve the drug targeting. In this review article, we highlight medically oriented micro-/nano-motors, in particular the ones created for targeted drug delivery, and discuss their current limitations and possibilities toward in vivo applications...
March 1, 2018: Therapeutic Delivery
Javier Adrián Calles, Maria Julia Mora, Renée Onnainty, Luis Ignacio Tartara, Gladys Ester Granero, Marcela Raquel Longhi, Yolanda Diebold, Enrique Marcelo Vallés, Santiago Daniel Palma
AIM: This work aimed to design and characterize cross-linked hyaluronic acid-itaconic acid films loaded with acetazolamide-hydroxypropyl β cyclodextrin-triethanolamine complexes. MATERIALS & METHODS: Films were cross-linked with itaconic acid and poly(ethyleneglycol)-diglycidylether. Biopharmaceutical properties were assessed by evaluating in vitro drug release rate, biocompatibility in a human corneal epithelial cell line, bioadhesiveness with pig gastric mucin, in vivo bioadhesion and efficacy...
February 1, 2018: Therapeutic Delivery
Ludger M Ickenstein, Patrick Garidel
Hydrogels are, from a commercial perspective especially because of their ease of production, attractive sustained-release systems for high potent immunoglobulins with short circulation half-lives. Hydrogel formulations can reduce the dosing frequency while maintaining therapeutically relevant drug concentrations locally as well as systemically. However, hydrogels have only limited loading capacities and release hydrophilic immunoglobulins typically within hours or days, whereas weeks or months would be more preferable...
February 1, 2018: Therapeutic Delivery
Elaine Harris
The present industry update covers the period 1-30 November 2017. Sources of information include company press releases, regulatory and patent agencies' notices, scientific literature and various news websites. A number of companies reported positive clinical trial results for therapeutic candidates enabled by different delivery strategies including Vascular Therapies, Adapt and Altemia. November also saw the announcement of some significant collaborations and acquisitions; Cerenis Therapeutics acquired Lypro Biosciences, which gives them access to a proprietary drug delivery nanotechnology platform, NanoDisk ® , and Takeda announced a collaboration with Portal Instruments to develop a needle-free delivery device for its biological therapeutics...
February 1, 2018: Therapeutic Delivery
Sonia Molesini, Federica Urto, Alexandra D Cvetkovska, Vincenzo Bettoli, Giuseppe Valacchi, Alessandra Pecorelli, Stefano Manfredini, Silvia Vertuani
AIM: We compared the performances of two different commercial products both based on betamethasone and an antibiotic but using different pharmaceutical vehicles: a polymer and lipid-enriched cream and a conventional oil-in-water emulsion. METHODOLOGY: Evaluation was conducted on a reconstructed human epidermis model. Moreover, skin barrier properties and cutaneous hydration of the two vehicles were evaluated on 20 human healthy volunteers. RESULTS: Overall, the polymer and lipid-enriched formulation works as a film-forming product that retains the therapeutic agent for a long time, ensuring its penetration and absorption through the skin, and promoting skin hydration...
February 1, 2018: Therapeutic Delivery
Thomas L Jones, Daniel M Neville, Anoop J Chauhan
Asthma and chronic obstructive pulmonary disease are primarily treated with inhaled medication, but delivery of that medication to its site of action is problematic; patients' ability to use inhalers will affect therapeutic response. Multiple inhaler devices are available but they are variably easy to use with consequent effects on compliance, intentional or otherwise. The Ellipta® device is a novel blister strip dry powder inhaler with medium resistance and a consistent delivered dose across a range of inspiratory flow rates...
February 1, 2018: Therapeutic Delivery
Asif Ahmed, Joshua Boateng
AIM: Diabetic foot ulcers are susceptible to infection and nonmedicated dressings are ineffective because they have no antimicrobial activity. This study aimed to develop antimicrobial films to deliver ciprofloxacin for treating bacterial infection. Results/methodology: Ciprofloxacin-loaded calcium alginate films were characterized for porosity, swelling, equilibrium water content, water absorption, water vapor transmission, evaporative water loss, moisture content, mechanical strength, adhesion, IR spectroscopy, scanning electron microscopy, x-ray diffraction, drug release, cytotoxicity and antimicrobial activity against Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa...
February 1, 2018: Therapeutic Delivery
Oliver C Steinbach
The present industry update covers the period 1 October-31 October 2017, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature. While the corporate news in October was traditionally dominated by the announcement of the third quarter results, with most of them showing market and revenue growth but also an increasing number of initial public offerings after years of slower financial development, we also saw trends continuing toward an increasing number of convergences of drugs with nanotechnology, devices and 21st century information technology...
February 2018: Therapeutic Delivery
Prit Lakhani, Akash Patil, Soumyajit Majumdar
Over the past decade, there has been a rise in the number of clinical cases of moderate to severe anterior segment ocular diseases. Conventional topical ophthalmic formulations have several limitations - to address which, novel drug-delivery systems are needed. Additionally, formidable physiological barriers limit ocular bioavailability through the topical route of application. During the last decade, various nano-scaled ocular drug-delivery strategies have been reported. Some of these exploratory, topical, noninvasive approaches have shown promise in improving penetration into the anterior segment tissues of the eye...
February 2018: Therapeutic Delivery
Alejandro J Paredes, Sergio Sánchez Bruni, Daniel Allemandi, Carlos Lanusse, Santiago D Palma
AIM: Albendazole (ABZ) is a broad-spectrum antiparasitic agent with poor aqueous solubility, which leads to poor/erratic bioavailability and therapeutic failures. Here, we aimed to produce a novel formulation of ABZ nanocrystals (ABZNC) and assess its pharmacokinetic performance in mice. Results/methodology: ABZNC were prepared by high-pressure homogenization and spray-drying processes. Redispersion capacity and solid yield were measured in order to obtain an optimized product. The final particle size was 415...
February 2018: Therapeutic Delivery
Purva Thatai, Bharti Sapra
AIM: The present investigation's intention was to develop an optimized nail lacquer (NL) for the management of onychomycosis. MATERIALS & METHODS: The NL was optimized statistically adopting 32 full factorial design having different polymer ratios and solvent ratios. The formulations were assessed for drug permeation drying time and peak adhesive strength of the film. Characterization was done using techniques including attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR), scanning electron microscopy (SEM), differential scanning calorimetry (DSC), x-ray diffraction (XRD), etc...
February 2018: Therapeutic Delivery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"